At a glance
- Originator Elorac
- Class Androstenes; Antiacnes; Antiandrogens; Antineoplastics; Azasteroids; Skin disorder therapies; Small molecules
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acne vulgaris
Most Recent Events
- 06 Jun 2017 Elorac completes a phase II trial in Acne vulgaris in USA (PO) (NCT02502669)
- 21 Mar 2017 Finasteride is still in phase II trials for Acne vulgaris in USA (PO)
- 01 Jul 2015 Phase-II clinical trials in Acne vulgaris in USA (PO) (NCT02502669)